Pharmacogenomics and patient stratification at FoG London 2027
Jan 27–28, 2027 London, UK ~8.3k attendees Website
16 organizations at FoG London 2027 present work in pharmacogenomics & patient stratification: 9 NHS, government and non-profit bodies, 4 universities and research institutes and 3 suppliers and service providers. Between them they bring 56 presentations to the program. Most represented: UCL, University of Cambridge and Queen Mary University of London. As of Oct 29, 2026.
Format
Top represented
Showing 1–6 of 16 organizations
| Organization | FoG London 2027 Attendance |
|---|---|
UCL London, UK | |
Multidisciplinary London research university with faculties of medical, life, brain and population health sciences, including the Great Ormond Street Institute of Child Health. | Talk Wed Jan 27 11:30–12:00 What Do We Need to Get More Advanced Therapies to Patients? How regulatory changes in the US, UK and EU, plus practical rollout models, could bring more advanced therapies to patients. Talk Wed Jan 27 12:30–13:00 Quantitative Proteomics to Unravel Signaling in Rare Cells How mapping protein phosphorylation in just hundreds of cells reveals dormant, drug-resistant glioblastoma cells and leftover disease in acute myeloid leukaemia. Talk Wed Jan 27 14:30–15:00 Resolving RNA Diversity in Neurodegenerative Disease: From Mechanism to Therapeutic Targeting How large human brain RNA datasets link disease-associated genetic variants to genes and mechanisms in Lewy body disorders and related neurodegenerative diseases. Talk Wed Jan 27 15:30–16:00 Tracing Metastatic Evolution with Spatial Biology: Insights for Immunity and Immune Evasion How mapping cells in place across primary tumours and their metastases reveals the earliest steps of cancer spread and immune escape. Talk Wed Jan 27 15:30–16:00 Why Does the Food Environment Affect Us Differently? What it means to call obesity genetic, how genes and food surroundings interact to shape weight, and what a twin study shows. Population & social genomics Talk Wed Jan 27 16:30–17:00 Personalised Surveillance in Ovarian Cancer: Does It Work? Whether tracking a blood tumour marker over time helps women at high genetic risk of ovarian cancer who are awaiting preventive surgery. Talk Wed Jan 27 16:30–17:00 Why Do We Age So DIfferently? Why people with similar genes and lifestyles age at different rates, and what genetically identical organisms reveal about chance in ageing. Population & social genomics Talk Thu Jan 28 10:30–11:00 Who Do We Think We Are? What the Last Decade of Genomics Has Revealed About Us What ancient DNA has revealed about human migration and ancestry, and what genetics can and cannot say about race and identity. Population & social genomics Talk Thu Jan 28 11:30–12:00 Ageing as a Modifiable Process: From Lifestyle to Therapeutic Intervention How exercise, sleep, diet and social life shape ageing, and whether existing drugs could target ageing biology to delay disease. Talk Thu Jan 28 11:30–12:00 Talk Thu Jan 28 12:30–13:00 Rewriting the Rules: Gene Therapy and Clinical Trials in Pregnancy Why pregnant women were long excluded from clinical trials, how pregnancy research can now run safely, and what fetal gene therapy could offer. Panel Thu Jan 28 14:40–15:10 What Will Human Evolution Look Like Next? Evidence that humans are still evolving, and how disease, climate, migration and gene editing could shape where evolution goes next. Population & social genomics Talk Thu Jan 28 16:10–16:40 25 Years of Gene Therapy for Inherited Immune Disorders: Progress and Future Potential How gene and cell therapies are moving from experiments toward potential cures for inherited blood diseases and cancer, and what blocks wider access. Talk Thu Jan 28 16:10–16:40 Critical Appraisal of Polygenic Risk Scores and Circulating Proteins for Screening, Risk Stratification and Individual Risk Prediction How to judge whether polygenic risk scores and blood protein markers really help with screening, risk grouping and predicting individual disease risk. Talk Thu Jan 28 16:40–17:10 From Research to Reality: Ensuring Women Benefit from Innovation How to design women's health tests and technologies that work for all women, and who risks being left behind by them. |
University of Cambridge Cambridge, UK | |
Collegiate research university in Cambridge, England, whose School of Clinical Medicine sits on the Cambridge Biomedical Campus beside Addenbrooke's Hospital. | Talk Wed Jan 27 11:30–12:00 Integrating Spatial Multi-Omics: From Technology Development to Biological Discovery How combining RNA and protein maps of tissue shows how ovarian tumour cells interact with immune cells across body sites and tumour types. Talk Wed Jan 27 11:30–12:00 Preeclampsia and Fetal Growth Restriction: From Prediction to Prevention How tracking proteins, RNA and metabolites through pregnancy could flag placental problems like preeclampsia and fetal growth restriction before symptoms appear. Talk Wed Jan 27 15:30–16:00 Tracking the Emergence and Spread of Antimicrobial Resistance Through Bacterial Genomics How building family trees from bacterial genomes dates the rise of drug-resistant strains, measures policy effects and traces hospital outbreaks. Talk Wed Jan 27 16:30–17:00 Beyond Single-Gene Testing: Using Polygenic Risk to Guide Precision Treatment How a person's overall genetic profile, not single genes, could show who benefits most from diabetes and high blood pressure treatments. Talk Wed Jan 27 17:30–18:00 From Stem Cell States to Stem Cell Flux: Navigating Cellular Landscapes Using scRNA Seq How single-cell RNA sequencing and computer models reconstruct the paths stem cells take as they change and choose their fates. Talk Wed Jan 27 17:30–18:00 Using AI and Spatial Multiomics to Decode Tumour Evolution and Identify High-Risk Cancer Why cancers with similar genetic drivers behave so differently, and how AI applied to maps of tumour tissue could flag aggressive cancers earlier. Talk Thu Jan 28 08:45–09:15 Why Are We Hungry? What Genomics Is Revealing About Appetite and Obesity What rare genetic cases, population studies and cell-by-cell brain maps reveal about the biology of appetite and obesity. Single-cell genomicsPopulation & social genomics Panel Thu Jan 28 14:10–14:40 Is Modern Life Fighting Our Human Biology? Whether modern food environments and inactive lifestyles clash with our evolved biology, and why genetics makes some people more prone to obesity. Population & social genomics Panel Thu Jan 28 14:40–15:10 What Will Human Evolution Look Like Next? Evidence that humans are still evolving, and how disease, climate, migration and gene editing could shape where evolution goes next. Population & social genomics Talk Thu Jan 28 15:10–15:40 Beyond Polygenic Risk Scores: Integrating Genetics and Multi-Omic Data for Personalised Risk Stratification and Earlier Screening How large international collaborations are improving cardiovascular risk prediction, and the evidence tying overweight and obesity to higher death rates. Talk Thu Jan 28 16:40–17:10 Longitudinal Tracking of Lung Cancer Clonal Dynamics using Circulating Tumour DNA How a method that reads very scarce tumour DNA in the blood tracks lung cancer's evolving cell populations and hints at hidden immunotherapy resistance. |
Queen Mary University of London London, UK | |
London research university with genomic medicine, computational biology, clinical pharmacology and population health research. | Talk Wed Jan 27 11:30–12:00 AI Agents for Rare Disease Diagnosis: Accelerating Variant Interpretation in Clinical Genomics How AI agents and large language models can speed up interpreting genetic variants for rare disease diagnosis within NHS genomic services. Talk Wed Jan 27 11:30–12:00 Pharmacogenomics in Healthcare How health systems could adopt pharmacogenomics, testing genes to guide prescribing, and whether to test in advance or only when needed. Talk Wed Jan 27 11:30–12:00 Proteomics to Identify Disease-Associated Variants in Patients with Rare Disease Undiagnosed After Genome Sequencing How unusually low blood protein levels could help diagnose rare disease patients left undiagnosed after whole-genome sequencing, and flag new disease genes. Talk Wed Jan 27 11:30–13:00 Interactive Session: Building Trust in AI – Identifying Bias, Data Leakage and Hidden Failure Modes AI in drug discovery & diagnostics Talk Wed Jan 27 15:30–16:00 Telomere Biology Disorders: Insights into Early-Life Programming and Lifelong Disease Risk How rare congenital disorders show why telomeres, the protective caps on chromosome ends, matter early in life and shape lifelong disease risk. Talk Thu Jan 28 14:10–14:40 From Genomic Risk to Precision Prevention: Transforming Women's Cancer Care How population genomic testing can find people at higher risk of women's cancers and guide targeted screening and prevention. Talk Thu Jan 28 15:10–15:40 A Human DNA Methylation Atlas for Epigenomic Interpretation How an atlas of DNA methylation marks across healthy human cell types helps interpret epigenetic data and cell-free DNA in blood. Talk Thu Jan 28 16:40–17:10 Rethinking Monogenic DIsease in the Era of Population Genomics How population-scale genome data and new ways to detect repeated DNA sequences are changing how single-gene diseases are understood. |
UK health research programme recruiting millions of adult volunteers who share health data and blood samples to study prevention and early detection. | Booth Exhibiting at Booth 106B Panel Wed Jan 27 10:20–11:00 The UK's Health Data Advantage: Powering the Future of Life Sciences What makes the UK's national genomic and health datasets valuable, and where they and AI could advance disease research and drug discovery. Biodata & bioinformatics Talk Wed Jan 27 14:30–15:00 Building the UK’s Health Data Ecosystem: What’s Next for Our National Genomic & Population Resources? Plans for the UK's major genomic and health data resources, and how to link them while protecting privacy and public trust. Talk Wed Jan 27 14:30–15:00 From Risk Prediction to Precision Prevention How large population cohorts let researchers study disease risk before symptoms appear, to find biomarkers and build evidence for prevention. Talk Wed Jan 27 14:30–16:00 Trust in the Data Age: Who Should Access Our Genomic Data and Why? Biodata & bioinformaticsPopulation & social genomics Talk Thu Jan 28 12:00–12:30 Finding The Right Participants For The Right Research How matching people by clinical, genetic or risk profile to suitable studies could speed recruitment for precision clinical research. |
Genomics England London, UK | |
Government-owned company providing whole-genome sequencing for the NHS Genomic Medicine Service and research, including the Generation newborn study. | Panel Wed Jan 27 10:20–11:00 The UK's Health Data Advantage: Powering the Future of Life Sciences What makes the UK's national genomic and health datasets valuable, and where they and AI could advance disease research and drug discovery. Biodata & bioinformatics Talk Wed Jan 27 14:30–15:00 Building the UK’s Health Data Ecosystem: What’s Next for Our National Genomic & Population Resources? Plans for the UK's major genomic and health data resources, and how to link them while protecting privacy and public trust. Talk Wed Jan 27 14:30–15:00 The Generation Study: Insights From a National Study of Newborn Genome Sequencing What a national study sequencing newborn genomes has learned so far about recruitment and results, and what it means for newborn screening. Talk Thu Jan 28 14:40–15:10 The Genomics England Adult Population Programme How Genomics England is designing a genomics programme for the adult population, what public engagement has taught, and its future plans. |
NHS trust running St George's Hospital in Tooting, a south-west London teaching hospital with clinical genetics services. | Talk Wed Jan 27 15:30–16:00 Beyond the Diagnostic Odyssey: What Comes After Genomic Diagnosis? How whole-genome sequencing is diagnosing children with rare developmental disorders, and what it takes to move from diagnosis to targeted treatment. Talk Wed Jan 27 17:30–18:00 Genotype-Guided Antiplatelet Therapy in Acute Ischemic Stroke Why some stroke patients resist the anti-clotting drug clopidogrel, and the evidence for and barriers to genetic testing that guides treatment. Talk Thu Jan 28 14:10–15:40 Behind the Result, Beyond the Report: Collaborative Case Discussions on Genomic Testing Dilemmas from Different Perspectives Genomic medicine & rare disease Talk Thu Jan 28 16:40–17:10 From Research to Reality: Ensuring Women Benefit from Innovation How to design women's health tests and technologies that work for all women, and who risks being left behind by them. |
Find buyers in pharmacogenomics & patient stratification
Tell us what you sell and we’ll find the people at organizations working on pharmacogenomics & patient stratification most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Browse FoG London 2027 by
Organization type
Topic
- Genomic medicine & rare disease 54
- Cancer genomics & diagnostics 31
- AI in drug discovery & diagnostics 43
- Biodata & bioinformatics 33
- Single-cell genomics 24
- Spatial biology 19
- Multi-omics & proteomics 31
- Epigenetics & translational omics 16
- Pharmacogenomics & patient stratification 16
- Women’s and children’s health 13
- Cell & gene therapy 18
- Microbiome & pathogen genomics 17
- Plant & agricultural genomics 13
- Population & social genomics 23
Exhibit hall
Everyone
Not affiliated with or endorsed by Front Line Genomics or the Festival of Genomics. Submit a correction